Xilio Therapeutics (NASDAQ:XLO – Get Rating) and Athersys (NASDAQ:ATHX – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.
Profitability
This table compares Xilio Therapeutics and Athersys’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xilio Therapeutics | N/A | -77.68% | -61.08% |
| Athersys | -1,362.14% | N/A | -193.59% |
Volatility and Risk
Xilio Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, Athersys has a beta of -0.74, meaning that its stock price is 174% less volatile than the S&P 500.
Institutional & Insider Ownership
Valuation & Earnings
This table compares Xilio Therapeutics and Athersys’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xilio Therapeutics | N/A | N/A | -$88.22 million | ($3.27) | -0.92 |
| Athersys | $2.41 million | 7.11 | -$72.53 million | ($4.66) | -0.20 |
Athersys has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings for Xilio Therapeutics and Athersys, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xilio Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| Athersys | 0 | 0 | 1 | 0 | 3.00 |
Xilio Therapeutics presently has a consensus target price of $11.25, suggesting a potential upside of 275.00%. Athersys has a consensus target price of $5.50, suggesting a potential upside of 491.40%. Given Athersys’ higher possible upside, analysts plainly believe Athersys is more favorable than Xilio Therapeutics.
About Xilio Therapeutics
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
About Athersys
Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. It engages in the discovery and development of therapies designed to extend and enhance the quality of human life. The firm offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
